Insider Trading Alert - JDSU, MLNX, BIIB, CAMP And PB Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 5, 2014, 146 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $51.84 to $26,546,700.00.

Highlighted Stocks Traded by Insiders:

JDS Uniphase Corp (CA (JDSU) - FREE Research Report

Jackson Rex S who is EVP & Chief Financial Officer at JDS Uniphase Corp (CA sold 1,660 shares at $12.83 on Feb. 5, 2014. Following this transaction, the EVP & Chief Financial Officer owned 49,727 shares meaning that the stake was reduced by 3.23% with the 1,660-share transaction.

Pollack Andrew R who is SVP, General Counsel at JDS Uniphase Corp (CA sold 1,660 shares at $12.83 on Feb. 5, 2014. Following this transaction, the SVP, General Counsel owned 0 shares meaning that the stake was reduced by 100% with the 1,660-share transaction.

Scrivanich Luke M who is Svp, Osp at JDS Uniphase Corp (CA sold 147 shares at $13.26 on Feb. 5, 2014. Following this transaction, the Svp, Osp owned 8,941 shares meaning that the stake was reduced by 1.62% with the 147-share transaction.

The shares most recently traded at $13.01, down $0.25, or 1.92% since the insider transaction. Historical insider transactions for JDS Uniphase Corp (CA go as follows:

  • 4-Week # shares sold: 3,680
  • 12-Week # shares sold: 3,680
  • 24-Week # shares sold: 112,818

The average volume for JDS Uniphase Corp (CA has been 5.2 million shares per day over the past 30 days. JDS Uniphase Corp (CA has a market cap of $2.9 billion and is part of the technology sector and telecommunications industry. Shares are down 2.35% year-to-date as of the close of trading on Wednesday.

JDS Uniphase Corporation provides communications test and measurement solutions, and optical products for telecommunications service providers, wireless operators, cable operators, network-equipment manufacturers, and enterprises worldwide. The company has a P/E ratio of 55.6. Currently there are 7 analysts that rate JDS Uniphase Corp (CA a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JDSU - FREE

TheStreet Quant Ratings rates JDS Uniphase Corp (CA as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full JDS Uniphase Corp (CA Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Mellanox Technologies (MLNX) - FREE Research Report

Shulman Yakov (Jacob) who is Chief Financial Officer at Mellanox Technologies sold 2,949 shares at $36.89 on Feb. 5, 2014. Following this transaction, the Chief Financial Officer owned 26,176 shares meaning that the stake was reduced by 10.13% with the 2,949-share transaction.

The shares most recently traded at $35.39, down $1.50, or 4.24% since the insider transaction. Historical insider transactions for Mellanox Technologies go as follows:

  • 4-Week # shares bought: 57,739
  • 4-Week # shares sold: 1,000
  • 12-Week # shares bought: 57,739
  • 12-Week # shares sold: 7,000
  • 24-Week # shares bought: 57,739
  • 24-Week # shares sold: 10,683

The average volume for Mellanox Technologies has been 698,300 shares per day over the past 30 days. Mellanox Technologies has a market cap of $1.6 billion and is part of the technology sector and electronics industry. Shares are down 11.11% year-to-date as of the close of trading on Wednesday.

Mellanox Technologies, Ltd., a fabless semiconductor company, produces and supplies semiconductor interconnect products for computing, storage, and communications applications in the high-performance computing, Web 2.0, storage, financial services, database, cloud, and embedded markets. The company has a P/E ratio of 39.5. Currently there are 5 analysts that rate Mellanox Technologies a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MLNX - FREE

TheStreet Quant Ratings rates Mellanox Technologies as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Mellanox Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Biogen Idec (BIIB) - FREE Research Report

DiPietro Kenneth who is EVP Human Resources at Biogen Idec sold 1,655 shares at $299.01 on Feb. 5, 2014. Following this transaction, the EVP Human Resources owned 0 shares meaning that the stake was reduced by 100% with the 1,655-share transaction.

The shares most recently traded at $303.54, up $4.53, or 1.49% since the insider transaction. Historical insider transactions for Biogen Idec go as follows:

  • 4-Week # shares sold: 2,020
  • 12-Week # shares sold: 17,459
  • 24-Week # shares sold: 34,385

The average volume for Biogen Idec has been 1.4 million shares per day over the past 30 days. Biogen Idec has a market cap of $72.8 billion and is part of the health care sector and drugs industry. Shares are up 10.23% year-to-date as of the close of trading on Wednesday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 34.4. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

CalAmp Corporation (CAMP) - FREE Research Report

Perna Frank Jr who is Director at CalAmp Corporation sold 8,300 shares at $28.02 on Feb. 5, 2014. Following this transaction, the Director owned 249,622 shares meaning that the stake was reduced by 3.22% with the 8,300-share transaction.

The shares most recently traded at $27.32, down $0.70, or 2.55% since the insider transaction. Historical insider transactions for CalAmp Corporation go as follows:

  • 4-Week # shares sold: 15,000
  • 12-Week # shares sold: 62,740
  • 24-Week # shares sold: 152,640

The average volume for CalAmp Corporation has been 742,100 shares per day over the past 30 days. CalAmp Corporation has a market cap of $1.0 billion and is part of the technology sector and telecommunications industry. Shares are down 1.97% year-to-date as of the close of trading on Wednesday.

CalAmp Corp. develops and markets wireless communications solutions that deliver data, voice, and video for critical networked communication and other applications primarily in the United States. The company has a P/E ratio of 21.2. Currently there are 3 analysts that rate CalAmp Corporation a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CAMP - FREE

TheStreet Quant Ratings rates CalAmp Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full CalAmp Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Prosperity (PB) - FREE Research Report

Epps Michael who is Executive Vice President at Prosperity sold 5,000 shares at $61.50 on Feb. 5, 2014. Following this transaction, the Executive Vice President owned 95,000 shares meaning that the stake was reduced by 5% with the 5,000-share transaction.

The shares most recently traded at $61.30, down $0.20, or 0.33% since the insider transaction.

The average volume for Prosperity has been 400,600 shares per day over the past 30 days. Prosperity has a market cap of $4.0 billion and is part of the financial sector and banking industry. Shares are down 3.64% year-to-date as of the close of trading on Wednesday.

Prosperity Bancshares, Inc. operates as the holding company for Prosperity Bank that provides a range of financial products and services to small and medium-sized businesses, and consumers in Texas. The stock currently has a dividend yield of 1.57%. The company has a P/E ratio of 16.7. Currently there are 2 analysts that rate Prosperity a buy, no analysts rate it a sell, and 13 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PB - FREE

TheStreet Quant Ratings rates Prosperity as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, compelling growth in net income, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Prosperity Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Dow Makes Move Higher as Bond Yields Hover Near 3% Threshold

Dow Makes Move Higher as Bond Yields Hover Near 3% Threshold

The Stock Market Isn't Rigged, Just Look At The Odds (VIDEO)

The Stock Market Isn't Rigged, Just Look At The Odds (VIDEO)

Let the Najarian Brothers Help You Generate Income With Options

Let the Najarian Brothers Help You Generate Income With Options

All Investors Can Trade Options, Just Ask the Najarian Brothers WATCH VIDEO

All Investors Can Trade Options, Just Ask the Najarian Brothers WATCH VIDEO

Aluminum Prices Plummet as U.S. Is Open to Easing Sanctions on Russia's Rusal

Aluminum Prices Plummet as U.S. Is Open to Easing Sanctions on Russia's Rusal